Article - 14/01/2021 Newly discovered RNA as growth driver in liver cancer Non-coding RNA (ncRNAs) molecules that do not encode proteins have many different functions, and some are associated with certain diseases. Prof. Dr. Sven Diederichs from the German Consortium for Translational Cancer Research and the German Cancer Research Center in Heidelberg has been conducting research into these molecules at the Freiburg University Medical Centre and discovered a ncRNA that regulates cell proliferation in cancer cells.https:////www.gesundheitsindustrie-bw.de:443/en/article/news/newly-discovered-rna-growth-driver-liver-cancer
Funding European Joint Programme on Rare Diseases Funding programme, Funded by: Horizon 2020, Submission deadline: 16/02/2021 https:////www.gesundheitsindustrie-bw.de:443/en/database/funding/european-joint-programme-rare-diseases
Press release - 11/01/2021 CureVac’s COVID-19 Vaccine Candidate, CVnCoV, Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating the induction of robust antibody and T cell responses of its COVID-19 vaccine candidate, CVnCoV, in non-human primates. https:////www.gesundheitsindustrie-bw.de:443/en/article/press-release/curevacs-covid-19-vaccine-candidate-cvncov-demonstrated-efficient-protection-non-human-primates-during-sars-cov-2-challenge-infe
Event - 12/07/2021 - 14/07/2021 Future Insight Days online, Kongress/Symposium https:////www.gesundheitsindustrie-bw.de:443/en/event/future-insight-days
Event - 23/02/2021 - 25/02/2021 Life-on-Chip Conference online, Registration deadline: 17/02/2021https:////www.gesundheitsindustrie-bw.de:443/en/event/life-chip-conference
Funding JOINT TRANSNATIONAL CALL 2021 Funding programme, Funded by: Horizon 2020, Submission deadline: 04/03/2021 https:////www.gesundheitsindustrie-bw.de:443/en/database/funding/joint-transnational-call-2021
Press release - 07/01/2021 CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV Bayer has signed a collaboration and services agreement with CureVac, a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid. Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV. https:////www.gesundheitsindustrie-bw.de:443/en/article/press-release/curevac-and-bayer-join-forces-covid-19-vaccine-candidate-cvncov
Infection control - 07/01/2021 Gene accordions as potential markers for pathogenic properties Bacteria must react to changes in the environment in order to survive. This is partly done by adapting genetic material, for example by multiplying and shortening individual genome segments. The research group led by Dr. Simon Heilbronner from the Interfaculty Institute of Microbiology and Infection Medicine at the University of Tübingen has shown that these so-called gene accordions are frequently found in the bacterium Staphylococcus aureus.https:////www.gesundheitsindustrie-bw.de:443/en/article/news/gene-accordions-potential-markers-pathogenic-properties
Press release - 22/12/2020 Voluntary or compulsory? New evidence on motivation for anti-Covid-19 policies A study by the University of Konstanz shows that voluntary motivation to comply with anti-Covid-19 policies is relatively high in Germany, but can be undermined by enforcement - The consequence of this finding differs depending on the policy.https:////www.gesundheitsindustrie-bw.de:443/en/article/press-release/voluntary-or-compulsory-new-evidence-motivation-anti-covid-19-policies
Press release - 09/12/2020 Combatting cancer with biological circuits The Freiburg engineer and biologist Prof. Dr. Barbara Di Ventura receives a Consolidator Grant from the European Research Council (ERC), one of the most prestigious prizes for European researchers, for her project "InCanTeSiMo - Intelligent cancer therapy with synthetic biology methods". Di Ventura will use the 2 Million Euros to develop a novel cancer treatment based on molecular methods from synthetic biology.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/combatting-cancer-biological-circuits
Funding INNO4COV-19 Project Funding programme, Funded by: Horizon 2020, Submission deadline: 31/03/2021 https:////www.gesundheitsindustrie-bw.de:443/en/database/funding/inno4cov-19-project
Digitalisation in Medicine - 08/12/2020 DiHeSys takes steps towards application Digital Health Systems GmbH (DiHeSys) has completed its founding phase and entered a new stage of development. This is reflected in the arrival of a new managing director, a strategic cooperation and its first pilot projects.https:////www.gesundheitsindustrie-bw.de/en/article/news/dihesys-takes-steps-towards-application
Press release - 07/12/2020 One for all AI-based evaluation of medical imaging data usually requires a specially developed algorithm for each task. Scientists from the German Cancer Research Center (DKFZ) have now presented a new method for configuring self-learning algorithms for a large number of different imaging datasets – without the need for specialist knowledge or very significant computing power.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/one-all
Development of the genomDE genome database - 04/12/2020 Whole genome sequencing for diagnosing rare diseases Grouped together, rare diseases are by no means a rare phenomenon; however, they are rarely correctly diagnosed and rarely properly treated. In most cases, there is no effective medication available. Rare disease centres staffed by experts have been set up in many German cities to speed up the often long and painful search for the right diagnosis and treatment. Whole genome sequencing is a component of general healthcare, used to identify…https:////www.gesundheitsindustrie-bw.de/en/article/news/whole-genome-sequencing-diagnosing-rare-diseases
Press release - 03/12/2020 HepaRegeniX achieves further milestone related to proof of safety and efficacy for MKK4 inhibition in an advanced chronic liver disease model New preclinical data indicate beneficial therapeutic effects in non-alcoholic steatohepatitis (NASH)-associated liver carcinomas.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/heparegenix-erreicht-meilenstein-mit-dem-nachweis-von-sicherheit-und-wirksamkeit-der-mkk4-inhibition-im-model-fuer-fortgeschritt
Press release - 01/12/2020 Novel vaccine trial to activate T-cell responses against SARS-CoV-2 A Phase I clinical trial using a self-developed vaccine against SARS-CoV-2 was initiated today at the University Hospital of Tübingen. In contrast to the currently evaluated vaccine candidates against COVID-19, the vaccine CoVAC1, developed by the Department of Immunology (Director Prof. Hans-Georg Rammensee) at the University of Tübingen, aims specifically at the induction of a T-cell-mediated immune response against SARS-COV-2.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/Novel-vaccine-trial-to-activate-T-cell-responses-against-SARS-CoV-2
Press release - 26/11/2020 New mechanism of action: A small-molecule degrades a cancer-promoting protein by gluing it into filaments “Molecular glue degraders” are a new class of cancer drugs, which “glue” cancer growth-promoting proteins directly to the molecular machinery of a cell’s disposal system, leading to the subsequent degradation of the cancer-driving proteins and anti-tumor activity. Scientists from Heidelberg and USA have now deciphered another mechanism whereby a small molecule can degrade a cancer protein. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/new-mechanism-action-small-molecule-degrades-cancer-promoting-protein-gluing-it-filaments
New method for analysing blood samples - 26/11/2020 Personalised therapy monitoring for malignant melanomas Immunotherapy has greatly improved the survival chances of patients with malignant melanoma. A study has now begun at the Department of Dermatology at the University Hospital of Tübingen to develop a way to monitor the course of treatment as effectively as possible. It involves personalised monitoring using liquid biopsies in addition to conventional PET/CT examinations. This analysis procedure of blood samples could enable closer monitoring of…https:////www.gesundheitsindustrie-bw.de/en/article/news/personalised-therapy-monitoring-malignant-melanomas
Press release - 17/11/2020 The Long Road to Dementia The chain reaction which leads to toxic protein deposits in Alzheimer’s disease starts even earlier than assumed. Researchers from Tübingen show how this process could be stopped early on.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/long-road-dementia
Press release - 16/11/2020 European Commission Announces That Tomorrow It Will Authorize the Agreement with CureVac for the Supply of up to 405 Million Doses of mRNA-Based COVID-19 Vaccine Candidate, CVnCoV CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), reports the European Commission’s announcement that tomorrow it will authorize an Advanced Purchase Agreement for CureVac´s mRNA-based COVID-19 vaccine candidate, CVnCoV.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/european-commission-announces-tomorrow-it-will-authorize-agreement-curevac-supply-405-million-doses-mrna-based-covid-19-vaccine
Funding COSME Funding programme, Funded by: Horizon 2020, Submission deadline: 19/01/2021 https:////www.gesundheitsindustrie-bw.de/en/database/funding/cosme
Lab-on-a-chip - 11/11/2020 Microfluidic platform for the best possible cancer therapy Every tumour and every patient is different, and there are individual reactions to drugs as well as the problem of resistance. Patient-specific cancer treatments require innovative and cost-effective approaches. The TheraMe! consortium has developed a novel instrument: a combination of microfluidic experiments and mathematical modelling for use in cancer precision medicine to prevent incorrect therapy options.https:////www.gesundheitsindustrie-bw.de/en/article/news/microfluidic-platform-best-possible-cancer-therapy
Press release - 09/11/2020 Making sense of what you see in biomedical images Sometimes an image is just an image. Sometimes it gives those who can read it correctly a deeper insight into what they can see. In many scientific disciplines, the key to extracting meaningful information from large three-dimensional images, obtained from X-ray tomography or optical microscopy, is segmentation, a tedious and time-consuming – and therefore error-prone – task if done manually. https:////www.gesundheitsindustrie-bw.de/en/article/press-release/making-sense-what-you-see-biomedical-images
Funding TRANSVAC: New Vaccines Faster Funding programme, Funded by: Horizon2020, Submission deadline: 15/12/2020 https:////www.gesundheitsindustrie-bw.de:443/en/database/funding/transvac-new-vaccines-faster
Press release - 09/11/2020 Infection diagnostics 3.0: Faster thanks to nanopore sequencing To ensure that sepsis patients receive appropriate antibiotics as quickly as possible, Fraunhofer IGB researchers have developed a diagnostic procedure that uses high-throughput sequencing of blood samples and delivers results much faster than conventional culture-based techniques. Thanks to the latest single-molecule sequencing techniques, this process has now been further improved so that pathogens can be identified after just a few hours.https:////www.gesundheitsindustrie-bw.de/en/article/press-release/infection-diagnostics-30-faster-thanks-nanopore-sequencing